144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study

A Bardia,S.A Hurvitz,Y.H Park,J.M Giltnane,P.D Pérez-Moreno,V Lopez Valverde,P.A Fasching,T.M Fernando,V Quiroga Garcia,C Xue,H.M Moore,J Steinseifer-Szabo

doi:10.1016/j.annonc.2022.07.179

144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study

A Bardia, S.A Hurvitz + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.179

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 5	License type: publisher-specific-oa

Affiliation: Samsung Medical Center, Massachusetts General Hospital, Harvard University, Roche (Canada), Roche (Switzerland)

#Hoffmann-La Roche Ltd #Roche Ltd + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study

Full Text